In a murine model of Ph+ ALL, imatinib treatment resulted in BCL6 upregulation and downregulation of p53, while genetic inactivation of BCL6 resulted in increased levels of p53 and failure to cause leukemia in mice. Here, BCL6 is linked to acute lymphoblastic leukemia.